Full-Time
Manufacturing Technician
Posted on 6/25/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
No salary listed
Minna, Inverin, Co. Galway, Ireland
In Person
 Biology & Biotech (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- Leaving certificate or equivalent qualification required
- 2-3 years working in a manufacturing environment, preferably Aseptic/Sterile Manufacturing
- Experience working in a cleanroom environment
- Third Level qualification in science or engineering discipline is an advantage but not essential
- Ability to build strong relationships and work within cross-functional teams
- Adaptability to work in a fast, dynamic environment whilst adjusting readily to meet unexpected constraints
- Drive, high energy, maturity, and ability to work under pressure, deliver results, and overcome obstacles
- Carry out daily tasks as assigned by the Production Manager according to GMP and the quality system
- Perform activities associated with the compounding, filling and capping of an aseptic process
- Prepare components and equipment for processing into a Grade A environment
- Accurately completing documentation on time, accurately and legibly
- Keeping the Manufacturing area tidy and clean
- Review and update documentation as requested by the Production Manager
- Participating in root cause analysis and problem-solving
- Completing compliant investigations and environmental excursions
- Adhering to all company standards in the area of safety, housekeeping and quality, notifying management of any discrepancies
- Follow gowning procedures on entry to areas
- Report any machine issues to the Production Manager and the maintenance department
- Set-up, clean and maintain equipment
- Transfer of waste material out of the cleanroom areas
- Perform environmental monitoring
- Participate in aseptic process simulations
- Adhere to and support all EHS & E standards, procedures, and policies
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- AbbVie raised 2026 revenue guidance twice, signaling stronger-than-expected commercial momentum.
- SKYRIZI Crohn's subcutaneous induction approval could accelerate sales from early 2027.
- WCLC 2026 data showed ABBV-1480 strong response rates, advancing AbbVie’s oncology credibility.
What critics are saying
- Humira-era antitrust and patent-thicket litigation still shadows AbbVie’s pricing strategy.
- A $10.9 billion Apogee deal increases execution risk before AbbVie proves multiple pipeline launches.
- ABBV-1480, Temab-A, and ABBV-706 remain unapproved; Phase 3 failures would hit growth hard.
What makes AbbVie unique
- SKYRIZI and RINVOQ drove $8.79 billion immunology revenue in Q2 2026.
- AbbVie owns multiple late-stage lung cancer assets, including ABBV-1480, Temab-A, and ABBV-706.
- The Allergan acquisition left AbbVie with Botox, aesthetics, and neuroscience diversification.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 3%AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.
AbbVie to present new data at WCLC 2026 Showcasing innovation across Lung Cancer pipeline. Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presentations span clinical, translational and real-world data across next-generation immunotherapies and targeted antibody-drug conjugates (ADCs), designed to generate insights into treatment burden, patient experience and biomarker identification that may help inform future research. "Our strategy in lung cancer is focused on building a complementary pipeline that brings together next-generation immunotherapies and targeted antibody-drug conjugates with the potential to address different aspects of tumor biology," said Daejin Abidoye, M.D., vice president and therapeutic area head of oncology, solid tumor and hematology at AbbVie. "Exploring the PD-1/VEGF approach represented by ABBV-1480 and the c-Met targeting by Temab-A are important elements of that strategy and may provide a foundation for potential novel combinations as we work to develop more tailored treatment approaches for people living with lung cancer." Advancing Novel Therapies Across Various Modalities in NSCLC Multiple presentations across AbbVie's NSCLC portfolio will showcase new studies and data analyses spanning multiple treatment modalities, highlighting first-line treatment approaches, patient experience and biomarker-informed research. AbbVie: leading the charge in Lung Cancer innovation. * ABBV-1480 (RC148): AbbVie, in partnership with RemeGen, will present Phase 1b data evaluating the investigational PD-1/VEGF bispecific antibody, ABBV-1480, in combination with platinum-based chemotherapy as a potential first-line treatment for advanced NSCLC. At the 10 mg/kg dose, identified as the recommended Phase 3 dose for further development in combination regimens in both squamous and non-squamous NSCLC, the primary endpoint of objective response rate (ORR) was 90.0% in squamous NSCLC (n=27/30) and 75.9% (n=22/29) in non-squamous NSCLC. The most common treatment-related adverse events (TRAEs) were a decrease in white blood cells, neutrophil, platelet counts and anemia. No grade >=3 hemorrhages with the 10 mg combinations were observed. This overall manageable safety profile supports ongoing Phase 3 development for this novel investigational asset.[1] * Telisotuzumab adizutecan (Temab-A), an investigational c-Met-directed ADC with a topoisomerase 1 inhibitor (Top1i) payload: Building on encouraging preliminary activity[2] observed in heavily pretreated patients, AbbVie initiated a Phase 1b/2 M24-536 study (NCT06772623). The study is evaluating a platinum-free combination of Temab-A and a PD-1 inhibitor, as a potential first-line treatment for advanced non-squamous NSCLC. The study includes analyses of c-Met and PD-L1 expression to identify the patients most likely to benefit from treatment.[3] Temab-A is also being studied in epidermal growth factor receptor (EGFR)-mutated NSCLC as monotherapy or in combination with osimertinib (NCT07155187). Clinical Data Showcasing the Potential of ABBV-706 in SCLC ABBV-706 is an investigational SEZ6-targeted ADC with a Top1i payload, being evaluated in SCLC. Presentations at WCLC include research that further characterizes the program and the potential role of SEZ6 in SCLC. * As previously reported, ABBV-706 demonstrated an ORR of 82% in patients with relapsed/refractory SCLC post platinum-based chemotherapy (n=17).[4] New safety analyses from 240 patients who received ABBV-706 monotherapy showed generally manageable hematologic and gastrointestinal toxicities, with the most common gastrointestinal events, including nausea (35.8%), vomiting (17.5%) and diarrhea (10.8%), being largely low grade and most requiring no dose adjustments.[5] Grade >=3 treatment-related pneumonitis or interstitial lung disease was reported in 1.7% of patients receiving ABBV-706 monotherapy.[6] Hematologic toxicities, including anemia, neutropenia and thrombocytopenia, were among the most common TRAEs.[5] Serious TRAEs occurred in 12.5% of patients. ABBV-706 is being evaluated as monotherapy in a Phase 3 study (NCT07365241) and in combination with atezolizumab in the Phase 2 study (NCT07155174), in SCLC. * Real-world research demonstrated that SEZ6 is broadly expressed in 91% of SCLC patients overall and in more than 96% of patients with brain or liver metastases. These findings further support SEZ6 as a potential therapeutic target in SCLC and other SEZ6-expressing tumors. [7] Additional details on key presentations are available below, and the full WCLC 2026 abstracts are available online. For information about AbbVie's clinical trial efforts in lung cancer, please visit clinicaltrials.gov. | Title | Date/Time | Session | Abstract Number | | Radiomic Biomarkers on Baseline CT Scans for Predicting Response to Teliso-V in NSCLC: A Machine Learning Approach | Monday, September 14 10:30AM-12:00PM KST | Poster Session: P2.077-248. Pathology and Biomarkers | P2.137. | | Telisotuzumab Adizutecan and PD-1 Inhibitor in Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer: A Phase 1b/2 Study | Monday, September 14 10:30AM-12:00PM KST | Poster Session: P2.304-390. Clinical Trials in Progress | P2.374. | | Efficacy and Safety of ABBV-706 Versus Standard of Care in Relapsed/Refractory Small Cell Lung Cancer: A Phase 3 Study | Monday, September 14 10:30AM-12:00PM KST | Poster Session: P2.304-390. Clinical Trials in Progress | P2.377. | | A Phase 3, Randomized, Double-Blind Trial of RC148 (ABBV-1480) Plus Chemotherapy in First-Line Squamous Non-Small-Cell Lung Cancer | Monday, September 14 10:30AM-12:00PM KST | Poster Session: P2.304-390. Clinical Trials in Progress | P2.379. | | Peripheral Neuropathy With Teliso-V in c-Met- Protein Overexpressing NSCLC in LUMINOSITY: Clinical Characteristics and PROs | Monday, September 14 2:17-2:25 PM KST | Poster Session: PT2.01. Metastatic NSCLC - Antibody-Drug Conjugate and Cytotoxic Therapy | PT2.01.05. | | Telisotuzumab vedotin Demonstrates Potent Antitumor Efficacy in Preclinical Models of Diffuse Pleural Mesothelioma | Monday, September 14 2:17-2:25 PM KST | Poster Session: PT2.05. Mesothelioma, Thymoma, and Other Thoracic Tumors | PT2.05.05. | | Hematologic and Gastrointestinal Toxicity of ABBV-706 in Advanced Solid Tumors: Safety Profile from the First-in-Human Study | Tuesday, September 15 9:30-11:00 AM KST | Poster Session: P3.282-354. Small Cell Lung Cancer and Neuroendocrine Tumors | P3.316. | | SEZ6 Is Expressed Across Major Clinical and Demographic Groups of SCLC Patients: Evidence From a US Clinicogenomic Database | Tuesday, September 15 9:30 AM-11:00 AM KST | Poster Session: P3.282-354. Small Cell Lung Cancer and Neuroendocrine Tumors | P3.340. | | RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic Non-Small- Cell Lung Cancer | Tuesday, September 15 12:52-1:02 PM KST | Oral Presentation Session: OA14. The Breakthrough Immunotherapy for Advanced NSCLC | OA14.01.03. | | High Burden and Limited Evidence in Late- Line ES-SCLC: A Structured Review of Clinical and Humanistic Outcomes | - | E-Poster EP13 Small Cell Lung Cancer and Neuroendocrine Tumors | EP13.05. | | Pneumonitis/Interstitial Lung Disease in the First-in-Human ABBV-706 Study: Incidence, Management, and Risk Factors | - | E-Poster EP13 Small Cell Lung Cancer and Neuroendocrine Tumors | EP13.32. | Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies. AbbVie holds exclusive rights from RemeGen to develop, manufacture, and commercialize ABBV-1480 outside of the Greater China territory. Emrelis(TM)(telisotuzumab vedotin-tllv) is an approved medicine being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses. U.S. Prescribing Information for AbbVie Medicines Please see full Prescribing Information for EMRELIS(TM)(telisotuzumab vedotin-tllv). More news. August 21, 2026 August 20, 2026 August 17, 2026
AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals
AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.
UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -